Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
130.67
-0.78 (-0.60%)
At close: Apr 28, 2026, 4:00 PM EDT
130.89
+0.22 (0.17%)
After-hours: Apr 28, 2026, 7:56 PM EDT
Inhibrx Biosciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Inhibrx Biosciences stock has a target of 150, which predicts an increase of 14.80% from the current stock price of 130.67.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Inhibrx Biosciences stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Initiates $150 | Strong Buy | Initiates | $150 | +14.80% | Apr 8, 2026 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 22, 2025 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | May 15, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 18, 2025 |
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 22, 2025 |
Financial Forecast
Revenue This Year
n/a
from 1.30M
Revenue Next Year
55.13M
EPS This Year
-5.57
from -9.04
EPS Next Year
-2.84
from -5.57
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 56.8M | ||||||
| Avg | n/a | 55.1M | ||||||
| Low | n/a | 53.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -5.74 | -2.93 | ||||
| Avg | -5.57 | -2.84 | ||||
| Low | -5.35 | -2.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.